Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | HINT1 | P49773 | 5/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.32 |
| ▸ | SARS1 | P49591 | 1/20 | 0.32 |
| ▸ | ADA | P00813 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612198 | 0.81 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1HINT1POLA1 | |
| SCHEMBL12714778 | 0.81 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1HINT1POLA1 | |
| SCHEMBL24181915 | 0.80 | KDM4E (0.56) | KDM4ETAS1R3TAS1R1HINT1POLA1 | |
| SCHEMBL26347587 | 0.80 | KDM4E (0.56) | KDM4ETAS1R3TAS1R1HINT1POLA1 | |
| SCHEMBL29138074 | 0.79 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1POLA1HPGD | |
| SCHEMBL22337173 | 0.79 | KDM4E (0.54) | KDM4ETAS1R3TAS1R1HINT1POLA1 | |
| SCHEMBL20654966 | 0.79 | KDM4E (0.54) | KDM4ETAS1R3TAS1R1HINT1POLA1 | |
| SCHEMBL22337233 | 0.79 | KDM4E (0.54) | KDM4ETAS1R3TAS1R1HINT1POLA1 | |
| SCHEMBL19127787 | 0.79 | KDM4E (0.54) | KDM4ETAS1R3TAS1R1HINT1POLA1 | |
| SCHEMBL29870290 | 0.79 | KDM4E (0.54) | KDM4ETAS1R3TAS1R1HINT1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | REL, RELA, NFKB1 | KDM4E 2520/4885TAS1R3 4693/4885TAS1R1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.